Integrated Investment Consultants LLC Takes $210,000 Position in Moderna, Inc. (NASDAQ:MRNA)

Integrated Investment Consultants LLC purchased a new position in shares of Moderna, Inc. (NASDAQ:MRNAFree Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 2,110 shares of the company’s stock, valued at approximately $210,000.

Several other hedge funds have also recently modified their holdings of the stock. First Pacific Financial purchased a new position in shares of Moderna in the third quarter valued at $27,000. ICA Group Wealth Management LLC bought a new stake in shares of Moderna in the 4th quarter valued at approximately $27,000. Stonebridge Capital Advisors LLC grew its stake in Moderna by 79.1% during the 1st quarter. Stonebridge Capital Advisors LLC now owns 283 shares of the company’s stock worth $49,000 after buying an additional 125 shares during the last quarter. Ancora Advisors LLC grew its stake in Moderna by 41.2% during the 1st quarter. Ancora Advisors LLC now owns 329 shares of the company’s stock worth $51,000 after buying an additional 96 shares during the last quarter. Finally, GPS Wealth Strategies Group LLC boosted its position in Moderna by 54.1% during the 3rd quarter. GPS Wealth Strategies Group LLC now owns 513 shares of the company’s stock worth $53,000 after acquiring an additional 180 shares during the period. 75.33% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Moderna news, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction dated Wednesday, March 27th. The shares were sold at an average price of $109.06, for a total value of $1,635,900.00. Following the sale, the director now owns 2,101,931 shares in the company, valued at $229,236,594.86. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other Moderna news, Director Noubar Afeyan sold 15,000 shares of Moderna stock in a transaction that occurred on Wednesday, March 27th. The shares were sold at an average price of $109.06, for a total value of $1,635,900.00. Following the completion of the sale, the director now owns 2,101,931 shares of the company’s stock, valued at approximately $229,236,594.86. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Shannon Thyme Klinger sold 544 shares of the business’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $99.05, for a total transaction of $53,883.20. Following the sale, the insider now directly owns 9,267 shares of the company’s stock, valued at approximately $917,896.35. The disclosure for this sale can be found here. Insiders sold a total of 65,021 shares of company stock valued at $6,847,342 over the last three months. Corporate insiders own 15.20% of the company’s stock.

Moderna Price Performance

Shares of MRNA traded down $1.05 during trading hours on Wednesday, reaching $102.56. The stock had a trading volume of 400,466 shares, compared to its average volume of 4,297,379. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.36 and a current ratio of 3.42. The company’s 50-day moving average is $99.23 and its two-hundred day moving average is $93.27. The stock has a market capitalization of $39.27 billion, a PE ratio of -8.35 and a beta of 1.62. Moderna, Inc. has a 12 month low of $62.55 and a 12 month high of $163.24.

Moderna (NASDAQ:MRNAGet Free Report) last issued its earnings results on Thursday, February 22nd. The company reported $0.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.78) by $1.33. Moderna had a negative net margin of 68.84% and a negative return on equity of 10.23%. The business had revenue of $2.80 billion for the quarter, compared to analysts’ expectations of $2.53 billion. During the same quarter in the previous year, the firm posted $3.61 EPS. The business’s revenue for the quarter was down 44.9% compared to the same quarter last year. Research analysts expect that Moderna, Inc. will post -7.48 EPS for the current year.

Wall Street Analysts Forecast Growth

MRNA has been the subject of several analyst reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a report on Thursday, March 28th. HSBC reaffirmed a “reduce” rating and set a $86.00 price target (up from $75.00) on shares of Moderna in a research note on Monday, February 26th. Royal Bank of Canada reissued an “outperform” rating and issued a $125.00 price objective on shares of Moderna in a research note on Thursday, March 28th. William Blair reaffirmed a “market perform” rating on shares of Moderna in a report on Monday. Finally, Oppenheimer raised Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 target price on the stock in a report on Tuesday, January 2nd. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $129.82.

Get Our Latest Analysis on MRNA

Moderna Company Profile

(Free Report)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Read More

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNAFree Report).

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.